Citius Pharmaceuticals, Inc. Lease, Cost
Citius Pharmaceuticals, Inc. (CTXR) reported Lease, Cost of $144.65 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-14
- Citius Pharmaceuticals, Inc. lease, cost for the quarter ending 2026-06-30 was $92.17K, a 27.31% increase year-over-year.
- Citius Pharmaceuticals, Inc. lease, cost for the quarter ending 2026-03-31 was $16.42K, a 75.52% decline year-over-year.
- Citius Pharmaceuticals, Inc. lease, cost for the quarter ending 2025-12-31 was $36.05K, a 40.87% decline year-over-year.
- Citius Pharmaceuticals, Inc. lease, cost for the quarter ending 2025-09-30 was $101.39K, a 23.97% increase year-over-year.
- Citius Pharmaceuticals, Inc. lease, cost for fiscal 2025 was $301.83K, a 14.06% increase from fiscal 2024.
- Citius Pharmaceuticals, Inc. lease, cost for fiscal 2024 was $264.63K, a 8.64% increase from fiscal 2023.
- Citius Pharmaceuticals, Inc. lease, cost for fiscal 2023 was $243.59K, a 1.67% increase from fiscal 2022.
- Citius Pharmaceuticals, Inc. lease, cost for fiscal 2022 was $239.59K, a 0.24% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $92.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $108.60K derived: sum of 2 quarters · filed 2026-08-14 | $144.65K 10-Q · filed 2026-08-14 | $246.04K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $16.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $52.48K 10-Q · filed 2026-05-15 | $153.86K derived: sum of 3 quarters · filed 2026-05-15 | $226.27K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $36.05K 10-Q · filed 2026-02-13 | $137.44K derived: sum of 2 quarters · filed 2026-02-13 | $209.84K derived: sum of 3 quarters · filed 2026-08-14 | $276.92K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-09-30 | $101.39K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $173.79K derived: sum of 2 quarters · filed 2026-08-14 | $240.87K derived: sum of 3 quarters · filed 2026-08-14 | $301.83K 10-K · filed 2025-12-23 | |
| 2025-06-30 | $72.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $139.48K derived: sum of 2 quarters · filed 2026-08-14 | $200.45K 10-Q · filed 2026-08-14 | $282.23K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $67.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $128.04K 10-Q · filed 2026-05-15 | $209.83K derived: sum of 3 quarters · filed 2026-05-15 | $270.80K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $60.97K 10-Q · filed 2026-02-13 | $142.75K derived: sum of 2 quarters · filed 2026-02-13 | $203.72K derived: sum of 3 quarters · filed 2026-02-13 | $264.69K derived: sum of 4 quarters · filed 2026-02-13 | |
| 2024-09-30 | $81.78K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $142.75K derived: sum of 2 quarters · filed 2025-12-23 | $203.72K derived: sum of 3 quarters · filed 2025-12-23 | $264.63K 10-K · filed 2025-12-23 | |
| 2024-06-30 | $60.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $121.94K derived: sum of 2 quarters · filed 2025-08-12 | $182.85K 10-Q · filed 2025-08-12 | $243.76K derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $60.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | $121.88K 10-Q · filed 2025-05-14 | $182.79K derived: sum of 3 quarters · filed 2025-05-14 | $182.79K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $60.91K 10-Q · filed 2025-02-14 | $121.82K derived: sum of 2 quarters · filed 2025-02-14 | $121.82K derived: sum of 3 quarters · filed 2025-02-14 | $243.64K derived: sum of 4 quarters · filed 2025-02-14 | |
| 2023-09-30 | $60.91K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | $60.91K derived: sum of 2 quarters · filed 2024-12-27 | $182.73K derived: sum of 3 quarters · filed 2024-12-27 | $243.59K 10-K · filed 2024-12-27 | |
| 2023-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-14 | $121.82K derived: sum of 2 quarters · filed 2024-08-12 | $182.69K 10-Q · filed 2023-08-14 | $242.39K derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $121.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $182.69K 10-Q · filed 2024-08-12 | $121.78K 10-Q · filed 2023-05-12 | $242.39K derived: sum of 3 quarters · filed 2024-08-12 | $302.87K derived: sum of 4 quarters · filed 2024-08-12 |
| 2022-12-31 | $60.87K 10-Q · filed 2024-02-14 | $120.57K derived: sum of 2 quarters · filed 2024-02-14 | $181.05K derived: sum of 3 quarters · filed 2024-02-14 | $240.75K derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-09-30 | $59.71K derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-29 | $120.18K derived: sum of 2 quarters · filed 2023-12-29 | $179.89K derived: sum of 3 quarters · filed 2023-12-29 | $239.59K 10-K · filed 2023-12-29 | |
| 2022-06-30 | $60.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-14 | $120.18K derived: sum of 2 quarters · filed 2023-08-14 | $179.89K 10-Q · filed 2023-08-14 | $239.59K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $59.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-12 | $119.41K 10-Q · filed 2023-05-12 | $179.12K derived: sum of 3 quarters · filed 2023-05-12 | $238.82K derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $59.70K 10-Q · filed 2023-02-10 | $119.41K derived: sum of 2 quarters · filed 2023-02-10 | $179.12K derived: sum of 3 quarters · filed 2023-02-10 | $238.82K derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-09-30 | $59.71K derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-22 | $119.41K derived: sum of 2 quarters · filed 2022-12-22 | $179.12K derived: sum of 3 quarters · filed 2022-12-22 | $239.02K 10-K · filed 2022-12-22 | |
| 2021-06-30 | $59.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-11 | $119.41K derived: sum of 2 quarters · filed 2022-08-11 | $179.31K 10-Q · filed 2022-08-11 | $240.41K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $59.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-12 | $119.61K 10-Q · filed 2022-05-12 | $180.71K derived: sum of 3 quarters · filed 2022-05-12 | $221.59K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $59.90K 10-Q · filed 2022-02-10 | $121.00K derived: sum of 2 quarters · filed 2022-02-10 | $161.88K derived: sum of 3 quarters · filed 2022-02-10 | $231.38K derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-09-30 | $61.10K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-15 | $101.98K derived: sum of 2 quarters · filed 2021-12-15 | $171.48K derived: sum of 3 quarters · filed 2021-12-15 | $228.83K 10-K · filed 2021-12-15 | |
| 2020-06-30 | $40.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-12 | $110.38K derived: sum of 2 quarters · filed 2021-08-12 | $167.72K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $69.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-13 | $126.84K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $57.35K 10-Q · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |